Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

Posted by Geri Gentry on Aug 5th, 2026

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total transaction of $120,300.00. Following the transaction, the insider owned 1,676,126 shares of the company’s stock, valued at approximately $13,442,530.52. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total transaction of $722,700.00.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $8.19 on Wednesday. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $10.08. The business’s fifty day simple moving average is $7.59 and its 200-day simple moving average is $6.79. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The company has a market cap of $1.41 billion, a PE ratio of 136.50 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The firm had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares during the period. Geode Capital Management LLC increased its holdings in shares of Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares during the period. State Street Corp raised its stake in shares of Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in shares of Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

Check Out Our Latest Research Report on Xeris Biopharma

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.